1. Home
  2. KPTI vs SHIM Comparison

KPTI vs SHIM Comparison

Compare KPTI & SHIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPTI
  • SHIM
  • Stock Information
  • Founded
  • KPTI 2008
  • SHIM 1990
  • Country
  • KPTI United States
  • SHIM United States
  • Employees
  • KPTI N/A
  • SHIM N/A
  • Industry
  • KPTI Biotechnology: Pharmaceutical Preparations
  • SHIM
  • Sector
  • KPTI Health Care
  • SHIM
  • Exchange
  • KPTI Nasdaq
  • SHIM Nasdaq
  • Market Cap
  • KPTI 66.7M
  • SHIM 57.8M
  • IPO Year
  • KPTI 2013
  • SHIM 2023
  • Fundamental
  • Price
  • KPTI $7.53
  • SHIM $1.69
  • Analyst Decision
  • KPTI Strong Buy
  • SHIM Hold
  • Analyst Count
  • KPTI 5
  • SHIM 2
  • Target Price
  • KPTI $61.00
  • SHIM $3.00
  • AVG Volume (30 Days)
  • KPTI 144.0K
  • SHIM 10.4K
  • Earning Date
  • KPTI 05-07-2025
  • SHIM 03-13-2025
  • Dividend Yield
  • KPTI N/A
  • SHIM N/A
  • EPS Growth
  • KPTI N/A
  • SHIM N/A
  • EPS
  • KPTI N/A
  • SHIM N/A
  • Revenue
  • KPTI $145,237,000.00
  • SHIM $514,746,000.00
  • Revenue This Year
  • KPTI $4.37
  • SHIM N/A
  • Revenue Next Year
  • KPTI $19.07
  • SHIM $3.01
  • P/E Ratio
  • KPTI N/A
  • SHIM N/A
  • Revenue Growth
  • KPTI N/A
  • SHIM N/A
  • 52 Week Low
  • KPTI $5.90
  • SHIM $1.47
  • 52 Week High
  • KPTI $24.75
  • SHIM $7.99
  • Technical
  • Relative Strength Index (RSI)
  • KPTI 43.25
  • SHIM 26.46
  • Support Level
  • KPTI $5.90
  • SHIM $1.62
  • Resistance Level
  • KPTI $8.45
  • SHIM $1.85
  • Average True Range (ATR)
  • KPTI 1.06
  • SHIM 0.14
  • MACD
  • KPTI -0.01
  • SHIM -0.03
  • Stochastic Oscillator
  • KPTI 36.38
  • SHIM 1.59

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

About SHIM Shimmick Corporation

Shimmick Corp is a leading provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.

Share on Social Networks: